Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in Mice

By afschroeder • February 12, 2026

Leal S, Denardo A, Van Echten A, Jungnickel H, Nelson CB, Sandoval D, Salvador JA, Shin J, Chung A, Brush M, Bennett CP, Piermatteo A, Secrest P, Jung CL, Ganz T, Poli M, Gordts P. Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in Mice. Blood Adv. 2026 Feb 11:bloodadvances.2025017943. doi: 10.1182/bloodadvances.2025017943. Epub ahead of print. PMID: 41671472.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC,[...]

Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing

Lee Y, Feng J, Rahrooh A, Bui AAT, Cooper CB, Hsu JJ. Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing.[...]